Advaxis Inc. buy melinda
Startpreis
11.09.18
/
50%
11,67 €
Kursziel
23.01.19
18,94 €
Rendite (%)
-62,22 %
Endpreis
23.01.19
4,41 €
Zusammenfassung
Diese Einschätzung wurde am 23.01.19 mit einem Endkurs von 4,41 € beendet. Stark abwärts ging es für die BUY Einschätzung von melinda zu Advaxis Inc. mit einer Rendite von -62,22 %. melinda hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Advaxis Inc. | - | - | - | - |
iShares Core DAX® | 1,40 % | -0,27 % | 17,64 % | 15,58 % |
iShares Nasdaq 100 | 2,29 % | 6,91 % | 37,65 % | 51,52 % |
iShares Nikkei 225® | 1,62 % | 3,04 % | 12,91 % | 8,24 % |
iShares S&P 500 | 0,66 % | 3,69 % | 29,43 % | 44,24 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Advaxis Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 19/12 Publication de résultats
Develops immunotherapies for cancer and infectious diseases
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies.
It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins.
It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy.
The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies.
It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins.
It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy.
The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
Nombre d'employés : 108 personnes.
(Vom Mitglied beendet)